Introduction {#s1}
============

The highly polymorphic Human Leukocyte Antigen (HLA) genetic region encompasses many pseudogenes; little attention is paid to these compared to class I and II genes involved in clinical fields, such as immune diseases, anthropology matters, and the early migration of *Homo sapiens* ([@B1], [@B2]). The pseudogene *HLA-H* is located at 55 Kbp from the telomeric side of *HLA-A* and, due to their high similarity, these genes were described as sharing a recent ancestor ([@B3]--[@B5]).

*HLA-H* was defined as a non-functional gene because of its deletion from chromosomes carrying *HLA-A*\*23/^\*^24 alleles ([@B6]--[@B11]), but also because its amino acid sequence predicted a potentially non-functional truncated protein.

In a previous study, we identified 13 novel *HLA-H* alleles, which showed unexpected genetic diversity, with a total of 25 second-field alleles ([@B10]). Among these, *H*\**02:07* and *H*\**02:14* potentially encode complete transmembrane HLA proteins; while the *H*\**02:14* allelic frequency was very low, *H*\**02:07* displayed global worldwide frequencies of 8.6% that reached 19.6% in East Asian populations ([@B10]).

Functional implications of a putative HLA-H protein, however, remain difficult to explore as, to date, there is no validated HLA-H antibody. Nevertheless, the transcriptional activity of this gene has been assessed in different studies ([@B12]--[@B14]).

Like the non-classical class I molecules, HLA-G, -E, and -F, which display immune response activation and inhibition ([@B15]--[@B21]) HLA-H may be tolerogenic and participate in immune homeostasis. In cases where the immune system is challenged, the absence of HLA-H might lessen tolerogenicity; in Lung Transplant patients (LTx), the *HLA-G*\**01:04* allele, in Linkage Disequilibrium (LD) with *HLA-H*\**deletion*, was associated with impaired long-term survival, increased Chronic Lung Allograft Dysfunction (CLAD) occurrence, and the production of *de novo* Donor Specific Antigen (DSA) ([@B22]). The impaired outcome associated with *HLA-G*\**01:04* remains unclear as the HLA-G^\*^01:04 protein, which differs from G^\*^01:01 in its peptide anchor profile, increased protection from Natural Killer cells (NK) lysis compared to other alleles (in cytotoxicity assays with K562 cells) ([@B23]). Several causes may be considered, however, such as antigenicity elicited by HLA-G^\*^01:04 or reduced HLA-G expression in *HLA-G*\**01:04* carriers; however, it could also be due to the absence of *HLA-H* with the *HLA-G*\**01:04* haplotype.

HLA-H may act like HLA-G, -E, and -F, both directly as a transmembrane molecule and/or indirectly via its signal peptide by mobilizing HLA-E to the cell surface. HLA-E, which regulates NK and cytotoxic T-lymphocyte cells via the inhibitory receptor CD94/NKG2 ([@B16], [@B18], [@B19]), is transcribed in most tissues ([@B24]) but is mobilized to the cell surface by signal peptides from HLA Ia, HLA-G, and peptide ligands from stress proteins and viruses ([@B25], [@B26]).

The aims of the present study were to explore the expression and possible function of the HLA-H molecule. Lacking a validated tool to analyze the putative HLA-H transmembrane protein, we analyzed *HLA-H* RNA expression in Peripheral Blood Mononuclear Cells (PBMC), Human Bronchial Epithelial Cells (HBEC), and available RNA sequencing data from lymphoblastoid cell lines, and we looked to see whether HLA-E molecules were mobilized at the cell surface by the HLA-H signal sequence.

Materials and Methods {#s2}
=====================

Primary Cells
-------------

Peripheral Blood Mononuclear Cells (PBMC) were obtained from Ethylene Diamine Tetra Acetate-anticoagulated (EDTA) peripheral blood samples from healthy donors. The donations were collected in accordance with the French blood donation regulations and ethics and with the French Public Health Code (article L.1221-1).

Human Bronchial Epithelial Cells (HBEC) were obtained from human transplant donor lungs deemed unsuitable for transplantation and donated to medical research. The ethics committees of the institutions involved approved this study (CERC-SFCTCV-2018-5-6-9-8-32-DjXa). Primary human bronchial epithelial cells were isolated by protease digestion of human airways, and cells were cultivated under Air-Liquid Interface (ALI) conditions, as previously described ([@B27]). HBEC were maintained in culture for 21 days to obtain a differentiated cell population with a mucociliary phenotype.

K562 (ACC86) cell lines, used as the negative control for HLA expression, were obtained from the German Collection of Microorganisms and Cell Cultures (Leibniz Institute DSMZ, Germany).

HLA-H Transcriptional Expression
--------------------------------

### HLA-H Transcriptional Expression in PBMC and Bronchial Epithelial Cells

*HLA-H* transcriptional expression was investigated in PBMC and HBEC from healthy donors (*N* = 5 and *N* = 8, respectively). K562 cells (ACC86) were used as the negative control. Total RNA was isolated using the RNeasy kit (Qiagen, France). cDNA was reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen), and Real-time PCR analyses were performed using TaqMan technology (Life Technologies) as previously described ([@B28]). The primers/probes were designed using the Primer 3 v.0.4.0 program (<http://bioinfo.ut.ee/primer3-0.4.0/primer3/>) to specifically target *HLA-H* as checked with the Human Genome Browser (<http://genome.ucsc.edu/>) ([@B29]) and IPD-IMGT/HLA database 3.37.0 ([@B30]) ([Supplementary Table 1](#SM9){ref-type="supplementary-material"}). HLA-G and HLA-E were investigated as previously described ([@B28]), and *ACTB* (actinβ) was used as an endogenous control (ACTB Hs99999903_m1, Invitrogen).

Each experiment was carried out in duplicate, and average Ct was calculated with StepOne 2.1 software (Invitrogen), but Ct duplicates with a standard deviation above 0.5 were excluded.

### HLA-H Transcriptional Expression in Cell Line From the 1000 Genomes Project

*HLA-H* expression was also investigated in RNA-sequencing data from 464 lymphoblastoid cell lines from the 1000 Genomes Project ([@B31]).

RNA sequencing data were analyzed using PolyPheMe software specially designed for HLA NGS data analysis (Xegen, France) for which accuracy was assessed at 99.3% ([@B10], [@B32], [@B33]). This software is based on a specific strategy to avoid bias raised by the use of a unique genome as a reference for HLA NGS data mapping ([@B34]--[@B36]). First, RNAseq reads were selected for their specificity for *HLA* class I alleles. Then, all reads assigned to *HLA* class I were filtered out for their specificity for *HLA Ia* (*A, B, C*), *Ib* (*E, F, G*), and pseudogenes that showed the highest homology with *HLA-H*. Lastly, remaining reads were selected for their specificity for *HLA-H* using all exon sequences. The analysis was based on the 25 *HLA-H* alleles described in the IPD-IMGT/HLA database 3.37.0 ([@B30]), including the new alleles described in ([@B10]).

HLA-E Mobilization by HLA-H Signal Peptide
------------------------------------------

HLA-E mobilization by a HLA-H signal peptide was investigated in PBMC and HBEC using flow cytometry analysis.

Lyophilized signal peptides from HLA-H and from positive controls \[HLA-G, HLA-B15, and cytomegalovirus (CMV) ([@B37])\] were purchased from Invitrogen with 95% purity. Dimethylsulfoxyde (DMSO) and Neuromedin peptide (Sigma Aldrich) were used as reference and negative controls, respectively. All peptides were solubilized in DMSO at 50 mM. Peptide sequences are presented in [Supplementary Table 2](#SM10){ref-type="supplementary-material"}.

Cells were incubated as described in ([@B37]) with each peptide at a final concentration of 500 μM. Cells were incubated with the equivalent volume of peptide solvent (DMSO) as reference. PBMC with known *HLA-E* genotype were incubated at 37°C for 1, 2, 4, and 6 h. For HBEC, incubation at both interfaces (air and liquid) was performed at 37°C for 16 h. Each experiment was carried out in duplicate.

HLA-E expression at the cell surface was assessed by flow cytometry using a Mouse IgG1 antibody clone 3D12-PE (Invitrogen). The isotype control was a Mouse IgG1 antibody clone 679.1Mc7-PE (Beckman Coulter). Data were acquired on a FACSCalibur machine (BD Biosciences) and analyzed with BD FACSDiva software 6.1.2.

PBMC subtypes for HLA-E expression and overexpression after incubation with HLA-H were characterized with an antibody panel that included CD3-vioBlue (Miltenyi), CD19-AF700 (Biolegend), CD14-FITC (Biolegend), and viability Dye (eFluor506) (eBioscience) with or without a 3D12 antibody. Data were acquired on a Cytoflex machine (Beckman Coulter).

Statistical Analyses
--------------------

All association and correlation tests were performed with GRAPH PAD Prism 5 software (California USA). Differences between two modalities were tested using a Mann--Whitney *U* test. A Kruskal--Wallis one-way ANOVA followed by a Dunn *post-hoc* test was used to test more than two modalities. Q-PCR results were expressed as dCt (delta of cycle threshold, expression normalized by *ACTB* endogenous gene) with median and range \[min, max\]. RNA seq data from 464 lymphoblastoid cell lines from the 1000 Genomes Project were presented as the number of reads. HLA-E protein expression without peptide incubation was estimated as a percentage of expressing cells (cells gated in R2 and defined according to isotype control staining). The HLA-E mobilization at the cell surface upon peptide incubation was estimated and compared to incubation with a solvent (DMSO). Mobilization was assessed by the number of cells expressing HLA-E compared with DMSO (% gated in M2: cells with higher fluorescence than those incubated with DMSO), and by the ratio M2 Mean Fluorescence Intensity (MFI) median (cells incubated with peptide with gated cells in M2 \>1%)/M1 MFI median (cells incubated with DMSO).

Results {#s3}
=======

*HLA-H* mRNA Is Expressed in PBMC and HBEC
------------------------------------------

*HLA-H* transcriptional expression was measured using Real Time PCR. *HLA-H* primer/probe efficiency, estimated by 10-fold dilution of HBEC mRNA assays, was 2.05; no signal was observed with the gDNA assay or in K562 cells. All PBMC and HBEC samples expressed *HLA-H* \[5.334 (4.291--6.758) and 5.322 (4.268--8.410), respectively\] ([Figure 1](#F1){ref-type="fig"}).

![HLA-H expression in PBMC and HBEC (dCt: delta of cycle threshold, expression quantified by Q-PCR normalized by ACTB endogenous gene).](fimmu-10-02986-g0001){#F1}

In HBEC, *HLA-H* transcriptional expression was similar to that of *HLA-G*, both were lower than that of *HLA-E* (*p* \< 0.0001) ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}).

*HLA-H* mRNA Expression Is Lower in Hemizygous *HLA-H* Samples
--------------------------------------------------------------

*HLA-H* expression investigated in RNA-sequencing data from the 1000 Genomes Project ([@B31]) showed *HLA-H*-specific reads for 464 samples. As *HLA-H* is deleted from chromosomes bearing *HLA-A*\**23/*\**24* alleles, two samples bearing *HLA-A*\**24:02*/*24:02* and *HLA-A*\**23:01*/*24:02* showed 22 and 203 *HLA-H* reads, respectively, representing background noise. No attempt was made to correct this mismapping bias that is inherent to HLA NGS data mapping ([@B34]--[@B36]).

*HLA-H* expression in samples displaying one *HLA-A*\**23* or ^\*^*24* allele had statistically significant lower *HLA-H* reads \[*N* = 96, 192.6 (22--1,049)\] than samples with no *HLA-A*\**23* or ^\*^*24* allele \[*N* = 365, 334.8 (39--2,135) the outer value at 7,924 was excluded from analysis; *p* \< 0.0001\] ([Supplementary Figure 2](#SM2){ref-type="supplementary-material"}). This hemizygous effect was confirmed independently from allelic effect in genetically homogeneous samples with sufficient overall size: *H*\**01:01/HLA-A*\**23* or ^\*^*24* samples that displayed statistically significant lower *HLA-H* reads than *H*\**01:01/01:01* samples \[*N* = 29, 126.2 (46--227) vs. *N* = 37, 222.5 (78--623); *p* = 0.0002\] ([Supplementary Figure 3](#SM3){ref-type="supplementary-material"}).

*HLA-H* mRNA Expression Varies According to *HLA-H* Alleles
-----------------------------------------------------------

Expression of *HLA-H* mRNA differed according to *HLA-H* alleles in RNA-sequencing data from the 1000 Genomes Project; hemizygous samples (bearing *HLA-A*\**23* or ^\*^*24* alleles) showed low-expression alleles {*HLA-H*\**02:02* \[*N* = 4, 89.50 (72--129)\], *H*\**01:03* \[*N* = 5, 164.8 (99--229)\], *H*\**01:01* \[*N* = 29, 126.2 (46--227)\], *H*\**02:04* \[*N* = 17, 174.6 (38--493)\], *H*\**02:01* \[*N* = 13, 175.2 (72--267)\], medium-expression alleles {*H*\**02:10* \[*N* = 3, 284.3 (171--428)\], *H*\**02:05* \[*N* = 8, 255.1 (161--376)\], *H*\**02:08* \[*N* = 3, 441 (347--572)\]}, and a high-expression allele {H^\*^02:07 \[*N* = 3, 812.3 (383--1049)\]}; *p* \< 0.0001 ([Figure 2](#F2){ref-type="fig"}). This difference was confirmed in homozygous samples of sufficient overall size: low-expression alleles {*H*\**01:01/*\**01:01* \[*N* = 37, 222.5 (78--623)\], *H*\**02:04/*\**02:04* \[*N* = 18, 211.3 (39--537)\], *H*\**02:01/*\**02:01* \[*N* = 6, 181.8 (53--283)\]} and a medium-expression allele {*H*\**02:05/*\**02:05* \[*N* = 6, 487.5 (314--718)\]}; *p* = 0.0051 ([Supplementary Figure 4](#SM4){ref-type="supplementary-material"}). *H*\**02:070* of a higher expression was confirmed in samples bearing *H*\**01:01* and *H*\**01:01/*\**02:07* \[*N* = 20, 886.8 (353--1,455)\] vs. *H*\**01:01/*\**01:01* \[*N* = 37, 222.5 (78--623)\]; *p* \< 0.0001 ([Supplementary Figure 5](#SM5){ref-type="supplementary-material"}).

![HLA-H reads according to HLA-H alleles in hemizygous samples for HLA-H in RNA-sequencing data from the 1000 Genomes Project.](fimmu-10-02986-g0002){#F2}

HLA-E Molecule Is Mobilized at PBMC and HBEC Surface by HLA-H Signal Peptide
----------------------------------------------------------------------------

The expression of the HLA-E protein at the cell surface was studied using flow cytometry. All PBMC and HBEC expressed HLA-E without peptide incubation \[3D12 (anti-HLA-E) staining compared to isotype control\]. In PBMC, *HLA-E*\**01:03* homozygous individuals expressed more HLA-E than heterozygous individuals and *E*\**01:01* homozygous individuals \[74.88 (59.39--85.68); 59.79 (51.34--65.30); 39.55 (35.76--44.90), respectively, *p* = 0.0015\] ([Supplementary Figure 6](#SM6){ref-type="supplementary-material"}).

Incubation with CMV, HLA-B15, HLA-G, and HLA-H peptides significantly increased the number of cells expressing HLA-E after 4 and 6 h of incubation (*p* \< 0.01), whereas incubation with the negative control Neuromedin showed no effect ([Figure 3](#F3){ref-type="fig"}). In Neuromedin or DMSO assays, M2-gated cells never reached 1%.

![Percentage of PBMC overexpressing HLA-E compared with DMSO (defining M2) after 1, 2, 4, and 6 h of peptide incubation.](fimmu-10-02986-g0003){#F3}

Intensity of HLA-E mobilization at the cell surface was equivalent after incubation with an HLA-H peptide and with positive control peptides: no difference was observed between CMV, HLA-B15, HLA-G, and HLA-H (*p* = 0.469). Incubation duration significantly increased expression (*p* = 0.0014); the highest expression was reached after 4 h of incubation ([Figure 4](#F4){ref-type="fig"}).

![PBMC HLA-E overexpression after 1, 2, 4, and 6 h of peptide incubation (gated cells in M2 \>1%) compared with DMSO.](fimmu-10-02986-g0004){#F4}

PBMC cell subtype analysis showed that LT, monocytes, and LB overexpressed HLA-E after 4 h of HLA-H peptide incubation ([Supplementary Figure 7](#SM7){ref-type="supplementary-material"}).

In HBEC that were tested with one peptide control because of HBEC availability, HLA-E mobilization with HLA-H, and CMV peptides showed no statistical difference and were effective after 16 h of peptide incubation (*p* = 0.0273) compared to DMSO ([Supplementary Figure 8](#SM8){ref-type="supplementary-material"}).

Discussion {#s4}
==========

HLA pseudogenes have scarcely been studied and are poorly investigated, but some of them may still be functional. *HLA-H* was shown to be transcribed ([@B12]--[@B14]), and we formerly described unexpected worldwide genetic diversity ([@B10]). In different clinical studies, the *HLA-G*\**01:04* haplotype, in which *HLA-H* was deleted, was associated with an impaired outcome ([@B22], [@B38], [@B39]). The full-length HLA-H protein showed similar domains to non-classical class I molecules ([@B10]), HLA-G, -E, and -F, molecules, which displayed immune response activation and inhibition ([@B15]--[@B21]). Furthermore, the HLA-H signal peptide (MVLMAPRTLLLLLSGALALTQTWA) was almost identical to that of HLA-A (MAVMAPRTLLLLLSGALALTQTWA), except that there was a Valine in the second position as in HLA-G (MVVMAPRTLFLLLSGALTLTETWA), and there was a specific amino acid (Val\>Leu) in the third position, compared to other HLA class I proteins ([@B40]).

We thus hypothesized that HLA-H may have tolerogenic activity either as a transmembrane molecule and/or via its signal peptide by mobilizing HLA-E to the cell surface.

In this study, as there is still no validated anti-HLA-H antibody, we aimed to confirm *HLA-H* RNA expression in different primary cells and also to see whether the HLA-H signal peptide could mobilize HLA-E to the cell surface in a similar way to other HLA peptides.

We analyzed *HLA-H* RNA expression in Peripheral Blood Mononuclear Cells (PBMC), Human Bronchial Epithelial Cells (HBEC), and in RNA-sequencing data from 464 lymphoblastoid cell lines from the 1000 Genomes Project ([@B31]).

Our data support that *HLA-H* is transcribed in blood mononuclear cells and in primary epithelial cells ([@B12]--[@B14]). In HBEC, its expression is similar to that of *HLA-G*. RNA-sequencing data from lymphoblastoid cell lines from the 1000 Genomes Project allowed us to show a hemizygous effect in the expression of *HLA-H* and to characterize different levels of expression according to *HLA-H* alleles; most interestingly, the *HLA-H*\**02:07* allele, which potentially encodes a full-length protein, presents the highest level of mRNA expression. *HLA-H* expression results from RNA-sequencing data, but this should, however, be taken with precaution and needs further confirmation; a part of the reported expression level, notably in the low-expression alleles, may be due to mismapped reads, as observed in the *HLA-A*\**23* and/or ^\*^*24* samples and as reported in different studies dealing with HLA NGS mapping ([@B34]--[@B36]).

We then analyzed HLA-E mobilization at the cell surface by peptides from the HLA-H signal sequence. Physiologically, HLA-E is expressed at the surface of endothelial cells, T and B lymphocytes, monocytes, and macrophages ([@B41]). However, HLA-E, transcribed in most tissues ([@B24]), can be mobilized to the cell surface by different peptides, such as stress protein peptides and peptides derived from different pathogens ([@B16], [@B18]). We thus performed assays in PBMC, as described in ([@B37]), as well as in primary epithelial cells.

Our data showed that incubation with an HLA-H signal peptide mobilized HLA-E at the cell surface of T-Lymphocytes, monocytes, B-Lymphocytes, and primary epithelial cells. The incubation time required for a significant effect was compatible with cell properties, as peak expression was reached after 4 h in antigen-presenting cells and after 16 h in primary epithelial cells.

We confirmed that, physiologically, PBMC from *HLA-E*\**01:03* homozygous individuals had higher HLA-E cell surface expression than PBMC from *HLA-E*\**01:01* homozygous individuals. Functional differences between the two isoforms, HLA-E^\*^01:01 and HLA-E^\*^01:03, which display similar frequencies (50%) in different populations ([@B42]), involve relative peptide affinity, cell surface expression, and potential lytic activity on NK cells ([@B43]).

Whether HLA-E isoforms associated with the HLA-H signal peptide display different tolerogenic activity remains to be explored. The higher affinity of the HLA-G-derived non-amer-HLA-E complex with a CD94/NKG2C receptor complex was reported and explained by the 10th amino acid (Phe) in the HLA-G signal peptide ([@B44]). In HLA-H, this amino acid was identical to HLA-A (Leu) and different from HLA-G.

The fact that *HLA-H* ^\*^*02:07* is so widespread and that mRNA expression is high in cells suggests that this HLA pseudogene deserves further investigation. Our results suggest that *HLA-H* may be functional. Many questions, however, need to be addressed: different expressions according to *HLA-H* alleles must be confirmed in primary tissues, particularly concerning the *HLA-H*\**02:07* allele; *HLA-H* mRNA translation has to be explored, as our experiments were performed with a synthetic HLA-H signal peptide; and potential immune protection by HLA-E associated with an HLA-H signal peptide also has to be studied. Finally, supplementary studies will also be needed to investigate the existence and functional activity of a full-length HLA-H protein.
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